Hyperglycaemia and Its Prognostic Value in Patients with COVID-19 Admitted to the Hospital in Lithuania

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Jan 23

PMID 38255162

Authors

Lina Zabuliene

Ieva Kubiliute

Mykolas Urbonas

Ligita Jancoriene

Jurgita Urboniene

Ioannis Ilias

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Increased blood glucose levels atadmission are frequently observed in COVID-19 patients, even in those without pre-existing diabetes. Hyperglycaemia is associated with an increased incidence of severe COVID-19 infection. The aim of this study was to evaluate the association between hyperglycaemia at admission with the need for invasive mechanical ventilation (IMV) and in-hospital mortality in patients without diabetes who were hospitalized for COVID-19 infection.

Materials And Methods: This retrospective observational study was conducted at Vilnius University Hospital Santaros Clinics, Lithuania with adult patients who tested positive for severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 and were hospitalized between March 2020 and May 2021. Depersonalized data were retrieved from electronic medical records. Based on blood glucose levels on the day of admission, patients without diabetes were divided into 4 groups: patients with hypoglycaemia (blood glucose below 4.0 mmol/L), patients with normoglycaemia (blood glucose between ≥4.0 mmol/L and <6.1 mmol/L), patients with mild hyperglycaemia (blood glucose between ≥6.1 mmol/L and <7.8 mmol/L), and patients with intermittent hyperglycaemia (blood glucose levels ≥7.8 mmol/L and <11.1 mmol/L). A multivariable binary logistic regression model was created to determine the association between hyperglycaemia and the need for IMV. Survival analysis was performed to assess the effect of hyperglycaemia on outcome within 30 days of hospitalization.

Results: Among 1945 patients without diabetes at admission, 1078 (55.4%) had normal glucose levels, 651 (33.5%) had mild hyperglycaemia, 196 (10.1%) had intermittent hyperglycaemia, and 20 (1.0%) had hypoglycaemia. The oddsratio (OR) for IMV in patients with intermittent hyperglycaemia was 4.82 (95% CI 2.70-8.61, < 0.001), and the OR was 2.00 (95% CI 1.21-3.31, = 0.007) in those with mild hyperglycaemia compared to patients presenting normal glucose levels. The hazardratio (HR) for 30-day in-hospital mortality in patients with mild hyperglycaemia was 1.62 (95% CI 1.10-2.39, = 0.015), while the HR was 3.04 (95% CI 2.01-4.60, < 0.001) in patients with intermittent hyperglycaemia compared to those with normoglycaemia at admission.

Conclusions: In COVID-19 patients without pre-existing diabetes, the presence of hyperglycaemia at admission is indicative of COVID-19-induced alterations in glucose metabolism and stress hyperglycaemia. Hyperglycaemia at admission in COVID-19 patients without diabetes is associated with an increased risk of invasive mechanical ventilation and in-hospital mortality. This finding highlights the importance for clinicians to carefully consider and select optimal support and treatment strategies for these patients. Further studies on the long-term consequences of hyperglycaemia in this specific population are warranted.

References

Gerganova A, Assyov Y, Kamenov Z . Stress Hyperglycemia, Diabetes Mellitus and COVID-19 Infection: Risk Factors, Clinical Outcomes and Post-Discharge Implications. Front Clin Diabetes Healthc. 2023; 3:826006. PMC: 10012081. DOI: 10.3389/fcdhc.2022.826006. View

Plummer M, Bellomo R, Cousins C, Annink C, Sundararajan K, Reddi B . Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. Intensive Care Med. 2014; 40(7):973-80. DOI: 10.1007/s00134-014-3287-7. View

Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X . Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020; 22(10):1897-1906. PMC: 7283710. DOI: 10.1111/dom.14099. View

Zhang J, Kong W, Xia P, Xu Y, Li L, Li Q . Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease 2019. Front Endocrinol (Lausanne). 2020; 11:525. PMC: 7365851. DOI: 10.3389/fendo.2020.00525. View

Iacobellis G, Penaherrera C, Bermudez L, Mizrachi E . Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. Diabetes Res Clin Pract. 2020; 164:108185. PMC: 7251996. DOI: 10.1016/j.diabres.2020.108185. View

Li J, Li Y, Wang Z, Liu N, He L, Zhang H . Increased risk of new-onset diabetes in patients with COVID-19: a systematic review and meta-analysis. Front Public Health. 2023; 11:1170156. PMC: 10248182. DOI: 10.3389/fpubh.2023.1170156. View

McGuinness O . Defective glucose homeostasis during infection. Annu Rev Nutr. 2005; 25:9-35. DOI: 10.1146/annurev.nutr.24.012003.132159. View

Mamtani M, Athavale A, Abraham M, Vernik J, Amarah A, Ruiz J . Association of hyperglycaemia with hospital mortality in nondiabetic COVID-19 patients: A cohort study. Diabetes Metab. 2021; 47(3):101254. PMC: 7994287. DOI: 10.1016/j.diabet.2021.101254. View

Roy S, Demmer R . Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes. Transl Res. 2021; 241:52-69. PMC: 8575538. DOI: 10.1016/j.trsl.2021.11.002. View

10.

Vedantam D, Poman D, Motwani L, Asif N, Patel A, Anne K . Stress-Induced Hyperglycemia: Consequences and Management. Cureus. 2022; 14(7):e26714. PMC: 9360912. DOI: 10.7759/cureus.26714. View

11.

Gunst J, De Bruyn A, Van den Berghe G . Glucose control in the ICU. Curr Opin Anaesthesiol. 2019; 32(2):156-162. PMC: 6774765. DOI: 10.1097/ACO.0000000000000706. View

12.

Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y . Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020; 63(10):2102-2111. PMC: 7347402. DOI: 10.1007/s00125-020-05209-1. View

13.

Liu S, Zhang Q, Wang W, Zhang M, Liu C, Xiao X . Hyperglycemia is a strong predictor of poor prognosis in COVID-19. Diabetes Res Clin Pract. 2020; 167:108338. PMC: 7377976. DOI: 10.1016/j.diabres.2020.108338. View

14.

Coppelli A, Giannarelli R, Aragona M, Penno G, Falcone M, Tiseo G . Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care. 2020; 43(10):2345-2348. DOI: 10.2337/dc20-1380. View

15.

Rajsfus B, Mohana-Borges R, Allonso D . Diabetogenic viruses: linking viruses to diabetes mellitus. Heliyon. 2023; 9(4):e15021. PMC: 10102442. DOI: 10.1016/j.heliyon.2023.e15021. View

16.

Matias A, Manique I, Sabino T, Rego T, Mihon C, Panarra A . Absolute Hyperglycemia versus Stress Hyperglycemia Ratio for the Prognosis of Hospitalized Patients with COVID-19 in the First Months of the Pandemic: A Retrospective Study. Diabetes Ther. 2022; 14(2):335-346. PMC: 9793808. DOI: 10.1007/s13300-022-01347-4. View

17.

He X, Liu C, Peng J, Li Z, Li F, Wang J . COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors. Signal Transduct Target Ther. 2021; 6(1):427. PMC: 8674414. DOI: 10.1038/s41392-021-00822-x. View

18.

Nateghi S, Gomari M, Roudsari Y, Foroughi A, Mansouri F, Shiva A . Moderately hyperglycemia as an independent prognostic factor for the worse outcome of COVID-19. Prim Care Diabetes. 2022; 16(3):361-364. PMC: 8904151. DOI: 10.1016/j.pcd.2022.03.005. View

19.

Morse J, Gay W, Korwek K, McLean L, Poland R, Guy J . Hyperglycaemia increases mortality risk in non-diabetic patients with COVID-19 even more than in diabetic patients. Endocrinol Diabetes Metab. 2021; 4(4):e00291. PMC: 8420416. DOI: 10.1002/edm2.291. View

20.

Yang Y, Cai Z, Zhang J . Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis. Biosci Rep. 2021; 41(2). PMC: 7876597. DOI: 10.1042/BSR20203584. View